AXA Framlington Biotech R Inc (F0GBR04Z1C.L)
YHD - YHD Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
As of 06:07PM EDT. Market open.
AXA Framlington Biotech R Inc
Cœur Défense Tour B, La Défense 4
100, Esplanade du Général de Gaulle
Management information
Linden Thomson,Lead manager since 4 July 2012
Dani Saurymper joined AXA IM in April 2015 as Fund Manager for the AXA Framlington Health Fund. He joined from Barclays Capital where he was a senior equity research analyst covering European healthcare.
Morningstar style box
Yahoo partners with Morningstar, a leading market research and investment data group to help investors rate and compare funds on Yahoo Finance. The Morningstar Category is shown next to the Morningstar Style Box, which identifies a fund's investment focus, based on the underlying securities in the fund.
Morningstar category
While the investment objective stated in a fund's prospectus may or may not reflect how the fund actually invests, the Morningstar category is assigned based on the underlying securities in each portfolio. Morningstar categories help investors and investment professionals make meaningful comparisons between funds. The categories make it easier to build well-diversified portfolios, assess potential risk and identify top-performing funds. We place funds in a given category based on their portfolio statistics and compositions over the past three years. If the fund is new and has no portfolio history, we estimate where it will fall before giving it a more permanent category assignment. Where necessary, we may change a category assignment based on recent changes to the portfolio.
Fund overview
CategorySector Equity Biotechnology
Fund familyAXA Investment Managers UK Ltd
Net assetsN/A
YTD return18.94%
Yield0.00%
Morningstar rating★★★
Inception date25 Nov 2001
Fund operations
Last dividend0.00
Last cap gain0.00
Holdings turnover88.00%
Average for categoryN/A
Fees and expenses
ExpenseF0GBR04Z1C.LCategory average
Annual report expense ratio (net)0.00%0.00%
Prospectus net expense ratio0.00%N/A
Prospectus gross expense ratio0.00%N/A
Max 12b1 feeN/AN/A
Max front end sales load5.50%N/A
Max deferred sales loadN/AN/A
3-yr expense projection0N/A
5-yr expense projection0N/A
10-yr expense projection0N/A
© 2024 Yahoo. All rights reserved.